Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

132.02USD
23 Feb 2018
Change (% chg)

$2.11 (+1.62%)
Prev Close
$129.91
Open
$130.08
Day's High
$132.08
Day's Low
$130.04
Volume
1,641,212
Avg. Vol
2,194,484
52-wk High
$148.32
52-wk Low
$119.49

Chart for

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.75
Market Cap(Mil.): $354,674.41
Shares Outstanding(Mil.): 2,686.52
Dividend: 0.84
Yield (%): 2.55

Financials

  Industry Sector
P/E (TTM): -- 30.96 16.59
EPS (TTM): -- -- --
ROI: -- 14.08 35.07
ROE: -- 15.71 17.79

Amgen loses case over FDA denial of Sensipar pediatric exclusivity

A federal judge has ruled that the U.S. Food and Drug Administration acted reasonably when it declined last year to grant Amgen Inc a six-month period of marketing exclusivity for pediatric uses of its kidney drug Sensipar.

Feb 20 2018

BRIEF-Johnson & Johnson Medical Devices Companies Acquire Orthotaxy

* JOHNSON & JOHNSON MEDICAL DEVICES COMPANIES ACQUIRE ORTHOTAXY TO DEVELOP NEXT-GENERATION ROBOTIC-ASSISTED SURGERY PLATFORM IN ORTHOPAEDICS‍​

Feb 20 2018

FDA approves J&J prostate cancer treatment

The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's Erleada for use in prostate cancer patients whose disease has not spread but continues to grow despite hormone therapy.

Feb 14 2018

UPDATE 2-FDA approves J&J prostate cancer treatment

Feb 14 The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's Erleada for use in prostate cancer patients whose disease has not spread but continues to grow despite hormone therapy.

Feb 14 2018

FDA approves J&J prostate cancer treatment

Feb 14 The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's Erleada treatment for use with prostate cancer patients whose cancer has not spread but continues to grow despite hormone therapy.

Feb 14 2018

Drugmaker AbbVie boosts 2018 forecast, shares soar to record high

Drugmaker AbbVie Inc significantly boosted its 2018 earnings forecast on Friday with help from U.S. tax reform and said it hopes to accelerate dividend growth and share buybacks, sending its stock soaring to an all-time high.

Jan 26 2018

J&J mesothelioma talc trial postponed as N.J. judge reverses expert ruling

A New Jersey state court judge on Monday delayed the start of a trial by a man who said he developed mesothelioma from being exposed to Johnson & Johnson's talc products after reversing a previous ruling that had barred a defense expert from testifying.

Jan 23 2018

Netflix lifts S&P, Nasdaq; J&J, Procter hold Dow in check

NEW YORK U.S. stocks advanced on Tuesday, as strong results from Netflix helped lift the S&P and Nasdaq Composite, but the Dow Industrials were hemmed in by declines in Johnson & Johnson and Procter & Gamble. | Video

Jan 23 2018

Deals of the day-Mergers and acquisitions

Jan 23 The following bids, mergers, acquisitions and disposals were reported by 2030 GMT on Tuesday:

Jan 23 2018

US STOCKS-S&P, Nasdaq get Netflix boost; Dow dragged by J&J, Procter

* Dow down 0.07 pct, S&P 500 up 0.15 pct, Nasdaq up 0.56 pct (Updates to mid-afternoon, changes byline)

Jan 23 2018

Earnings vs. Estimates